Navigation Links
Surveyed U.S. Physicians Indicate That Xarelto and Apixaban Will Benefit From the Lack of Use of a Fast-Acting Injectable Anticoagulant in the Treatment and Secondary Prophylaxis of Deep Vein Thrombosis/Pulmonary Embolism
Date:3/27/2013

BURLINGTON, Mass., March 27, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that clinical data and the opinions of interviewed thought leaders indicate that there is little to distinguish between current regimens utilized for the treatment and secondary prophylaxis of deep vein thrombosis (DVT)/pulmonary embolism (PE), as these regimens are initiated with use of a short-term injectable anticoagulant prior to long-term anticoagulation with warfarin. However, Bayer/Janssen's Xarelto and Bristol-Myers Squibb/Pfizer's Eliquis are expected to displace current therapies for the treatment and secondary prophylaxis of DVT/PE. Surveyed U.S. emergency room physicians indicate that Xarelto and Eliquis have competitive advantages in efficacy, safety and tolerability and delivery.

(Logo:  http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

"We forecast that Xarelto will become the U.S. market leader in the treatment and secondary prophylaxis of DVT/PE, with a 22.4 percent patient share by 2021, closely followed by apixaban with 19.3 percent," said Decision Resources Analyst Eamonn O'Connor, Ph.D. "This is due to these agents' impressive results in clinical trials, and the fact that oral therapy can be initiated straight away, removing the need to begin therapy with a fast-acting injectable anticoagulant."  

The DecisionBase 2013 report entitled Therapies with Improved Safety and Delivery Profiles Are Set to Overtake Enoxaparin and Warfarin as Leading Treatments of DVT/PE also finds that surveyed U.S. and European emergency room physicians agree that the incidence of VTE-related mortality is one of the attributes that most influences their decisions regarding prescribing in the treatment and secondary prophylaxis of DVT and PE. Clinical data and the opinions of interviewed thought leaders indicate that current and emerging therapies have no advantage on this attribute over the sales-leading regimen of enoxaparin (Sanofi's Lovenox, generics) plus warfarin (Bristol-Myers Squibb's Coumadin, Eisai's Warfarin, generics).

According to insights from surveyed U.S. and European emergency room physicians and managed care organization (MCO) pharmacy directors, reducing the incidence of bleeding is one of the greatest unmet needs in the treatment and secondary prophylaxis of DVT/PE. Clinical data and the opinions of interviewed thought leaders indicate that the novel oral anticoagulants -- Xarelto, Eliquis, Boehringer Ingelheim's Pradaxa, Daiichi Sankyo's Lixiana -- have demonstrated the potential to partially fulfill this unmet need.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists
2. Surveyed U.S. and European Neurologists Agree that a Therapys Effect on Physical Disability is the Most Important Attribute Influencing Prescribing Decisions in Secondary-Progressive Multiple Sclerosis
3. According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC
4. Though Over One-Third of Rheumatologists Have Prescribed Xeljanz for Their Rheumatoid Arthritis Patients, Physicians are Still Concerned With the Drugs Limited Post-Marketing Experience and Risks of Infection and Malignancy
5. Sound Physicians Enters Agreement to Provide Hospitalist Services at Broward Health
6. U.S. Physicians Report Diabetic Nephropathy as the Renal Condition with the Highest Unmet Need for Treatment
7. Physicians Adoption of Velcade for the Treatment of Chronic Graft Versus Host Disease Will Drive Growth In This Market Through 2021
8. Physicians Capital Investments Receives "Outstanding Development Award" for Sandy, Oregon Project
9. Sunshine Act Survey: More Than 50% of Physicians Unprepared
10. iPad Altering Interaction between Pharma Sales Forces, Physicians, & Consumers
11. Harris Poll Study Links Emotional Connection to Physicians Trust in Pharmaceutical Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... RADNOR, Pennsylvania , 22. März 2017 ... führende unabhängige und weltweit tätige Anbieter von ... gibt heute den Erwerb von EPL Archives ... biologischer Stoffe, der Kunden im kompletten Zyklus ... bei Verwahrung von Proben, Speicherung von Dokumenten ...
(Date:3/22/2017)... DUBLIN , Mar 22, 2017 Research ... Packaging Market Analysis & Trends - Industry Forecast to 2025" ... ... at a CAGR of around 7.1% over the next decade to ... analyzes the market estimates and forecasts for all the given segments ...
(Date:3/22/2017)... March 22, 2017 Piramal Pharma ... (CDMO), held a special event to introduce the new ... Lexington, Kentucky . The inaugural event was ... Chairman Ajay Piramal, and Piramal Pharma Solutions CEO, ... ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... March 22, 2017 , ... Influence ... its digital marketing solutions have enabled Children’s Hospital of The King’s Daughters (CHKD) ... , Recognizing the value of a digital marketing approach, the 206-bed pediatric teaching ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Burke Medical Research ... translate advances in basic neuroscience at the BMRI labs into new and improved ... improve movement, vision, and cognition impaired by stroke, traumatic brain injury, cerebral palsy, ...
(Date:3/22/2017)... , ... March 22, 2017 , ... The Vanderbeck Agency, ... the greater Nassau County region, is embarking on a combined charity effort with the ... , For the last 25 years, the Great Neck Breast Cancer Coalition has worked ...
(Date:3/22/2017)... ... , ... Chris Humphrey Insurance Agency, a North Carolina firm offering asset protection ... region, is initiating a charity event to raise support for five year old Dillyn, ... on a Friday evening in September 2014. At the time, Dillyn was only four ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... for providers while creating a positive patient experience. , HealthiPASS has further ... and empowers patients by helping them understand their financial responsibility. “Our latest ...
Breaking Medicine News(10 mins):